Monte Carlo based determination of dose distribution for some patch sources employed for radionuclide skin therapy
- 33 Downloads
Several methods are introduced for skin cancer treatment. An encouraging method is radionuclide skin therapy, where high-energy beta emitting radionuclides such as 32P, 90Y, 188Re and 166Ho are employed for skin irradiation. This study aimed to calculate the dose distribution for mentioned radionuclides at different layers of skin phantom through Monte Carlo simulation. Depth dose distribution, transverse dose profile and isodose curves related to the patch sources under investigation were calculated by MCNPX code. All of calculations were performed inside a developed skin phantom. Obtained results were compared with those reported by other studies to evaluate the validity of simulations. The results showed that the 166Ho and 32P have steeper dose gradient within the depth which can lead to the better normal tissue sparing. Simulated depth dose distributions were in a good agreement with other published studies and confirmed the validity of performed simulations. The obtained transverse dose profiles at 0.2 mm depth had acceptable symmetry and flatness that can improve the dose uniformity within the target area. Calculated isodose curves showed that the 90% isodose level covers a circular area with the diameter of around 8 mm for all studied beta sources. From the results, it can be concluded that 166Ho and 32P are more effective in treatment of superficial skin lesions, while, 90Y and 188Re are more rational choices in treatment of deeply distributed skin tumors. Size of employed patch source should be based on the target area to minimize the delivered dose to the adjacent tissues.
KeywordsBeta radionuclide sources Dose distribution Skin cancer Monte Carlo simulation
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 4.Halthore AN, Stevens KR Jr, Chow JCL, Chen Z, Sun A, Knisely JPS (2016) Cancers of the skin, including Mycosis fungoides. In: Khan FM, Gibbons JP, Sperduto PW (eds) Khan’s treatment planning in radiation oncology, 4th edn. Lippincott Williams & Wilkins (Wolters Kluwer), Philadelphia, pp 527–549Google Scholar
- 15.Macey DJ, Williams LE, Breitz HB, Liu A, Johnson TK, Zanzonico PB (2001) A primer for radioimmunotherapy and radionuclide therapy: report of Task Group #7 AAPM Nuclear Medicine Committee. Medical Physics Publishing, MadisonGoogle Scholar
- 16.Azaiez F, Bracco A, Dobes J, Jokinen A, Korner GE, Maj A et al (2014) Nuclear physics for medicine, technical report. Nuclear Physics European Collaboration Committee (NuPECC), Strasburg. http://www.nupecc.org/pub/npmed2014.pdf. Accessed 20 May 2018
- 17.The beta spectra file to use for MCNP code (2003) http://www.doseinfo-radar.com/RADARDecay.html. Accessed 20 Jan 2018
- 18.Pelowitz DB (2008) MCNPX user’s manual, version 2.6.0. Los Alamos National Laboratory, Los AlamosGoogle Scholar
- 19.ICRP (2002) Basic anatomical and physiological data for use in radiological protection reference values: ICRP Publication 89. Ann ICRP 32(3–4)Google Scholar